ASC4KIDS = Asciminib in Pediatric Patients with CML [China, Europe, Japan, Republic of Korea, Russian Federation, Thailand, Turkey]

Study title

ASC4KIDS = Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Scientific title

A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors

Type of study

Pediatric trial



Current status


Other trial ID

CABL001I12201, NCT04925479, EudraCT no. 2021-001286-20

What is the purpose of the study

The aim of this study is to support development of asciminib in patients aged 1 to <18 years with PH+ CML-CP previously treated with one or more tyrosine kinase inhibitors (TKIs). Asciminib is not yet available for pediactric patients. The study will be conducted to identify the dose and assess the safety of asciminib as pediatric formulation.

What will happen during the study

There will be two treatment groups in this study:

  • A pediatric formulation group with patients aged 1 to <18 years who will receive a dose based on body weight (1.3 mg/kg). The dose will be given orally with food.
  • An adult formulation group with adolescent patients aged 14 to <18 years, weighing at least 40 kg, who will receive a flat dose of 40 mg orally twice daily under fasted conditions.

The total duration of the treatment period of the study will be 5 years (260 weeks). Participants who, according to Investigator’s judgement, are benefiting from study treatment will remain on treatment up to the completion of the treatment period.

Key inclusion criteria

This study includes male or female patients:

  • with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (PH+ CML-CP)
  • in the pediatric formulation group: who are at least 1 and less than 18 years of age at study entry;
    in the adult formulation group: who are at least 14 and less than 18 years of age with a body weight of at least 40 kg at study entry
  • who meet all laboratory values specified in the study protocol.
  • who have previously been treated with at least one TKI

Further criteria may apply. Please discuss these with your doctor or study staff.


Key exclusion criteria

This study does not include patients:

  • with a known presence of the T315I mutation prior to study entry
  • in second chronic phase of CML after previous progression to advanced phase (AP) or blast crisis (BC)
  • who have undergone hematopoietic stem cell transplantation or are planning to undergo allogeneic stem cell transplantation.

Further criteria may apply. Please discuss these with your doctor or study staff.

Estimated primary completion date

June 2026

Where can I find additional information

You can find a study description in the US register This is a database provided by the U. S. National Institutes of Health.
You can also find a study description in the EU Clinical Trials Register. This is a database hosted by the European Medicines Agency (EMA).
You can find another study description in the medical journal Blood.

Study sponsor

Novartis Pharmaceuticals

Scientific lead / contact

Novartis Pharmaceuticals

Principal investigator

Novartis Pharmaceuticals

Study centers / principal investigators


Novartis Investigative Site
Beijing, 100044

Novartis Investigative Site
Shanghai, 200127

Novartis Investigative Site
Tianjin, 300020

Novartis Investigative Site
Hangzhou, Zhejiang, 310005


Novartis Investigative Site
Bordeaux, 33076

Novartis Investigative Site
Lille, 59000

Novartis Investigative Site
Paris, 75019

Novartis Investigative Site
Poitiers, 86021


Novartis Investigative Site
Erlangen, 91054

Novartis Investigative Site
Essen, 45147

Novartis Investigative Site
Hamburg, 20246


Novartis Investigative Site
Athens, 115 27


Novartis Investigative Site
Budapest, 1094


Novartis Investigative Site
Genova, 16147

Novartis Investigative Site
Monza, 20900

Novartis Investigative Site
Torino, 10126


Novartis Investigative Site
Osaka, 534-0021

Novartis Investigative Site
Yokohama-city, Kanagawa, 232-8555

Novartis Investigative Site
Shinjuku-ku, Tokyo, 160 8582

Korea, Republic of

Novartis Investigative Site
Seoul, 03080

Novartis Investigative Site
Seoul, 05505


Novartis Investigative Site
Utrecht, CS, 3584


Novartis Investigative Site
Wrocław, 50367

Russian Federation

Novartis Investigative Site
Moscow, 117198

Novartis Investigative Site
Saint Petersburg, 197022


Novartis Investigative Site
Bangkok, 10400

Novartis Investigative Site
Khon Kaen, 40000

Novartis Investigative Site
Muang, Chiangmai, 50200


Novartis Investigative Site
Bursa, Gorukle, 16059

Novartis Investigative Site
Istanbul, 34093

United States


Dana Farber Cancer Institute Dept. of DFCI
Boston, Massachusetts, 02215
Principal Investigator: Jessica Pollard

New York

Columbia University Medical Center- New York
Presbytarian Herbert Iving Cancer Center
New York; New York, 10032
Principal Investigator: Nobuko Hijiya


Cinn Children Hosp Medical Center
Cincinnati, Ohio, 45229-3039
Principal Investigator: Benjamin Mizukawa


University of Utah Primary Childrens Hospital
Salt Lake City, Utah, 84132
Principal Investigator: Mallorie Heneghan